Female Infertility and IVF: Causes, Evaluation, and Treatment Planning

Medically reviewed on 6 November 2026 - Dr. Senai Aksoy
Woman reviewing fertility evaluation papers in a calm consultation room in slate and mint tones (AI-generated illustration)

Key Takeaways

Female infertility is not one disease. Problems with ovulation, tubes, the uterus, egg supply, or implantation can each stop pregnancy — alone or together. IVF can get around some barriers, especially damaged tubes. The useful first step is still finding the main obstacle.

Key evidence: ASRM: Fertility evaluation of infertile women (2026) WHO: Infertility PMOS (PCOS) and infertility overview (Collée et al., 2021)

When pregnancy is delayed, the first useful question is rarely “IVF or not?” It is what is blocking conception: ovulation, tubes, uterus, age-related egg quality, endometriosis — or more than one of these. In vitro fertilisation (IVF) has a clear place in that map. It is not, by default, the first step. Match the treatment to the barrier you have found.

What is female infertility?

Female infertility usually means no pregnancy after 12 months of regular unprotected intercourse — or after about 6 months from age 35. The label covers problems with ovulation, tubes, uterus, ovarian reserve, or implantation.

ASRM and WHO treat infertility as a disease of the reproductive system. Naming the cause early helps avoid both delay and unnecessary treatment (ASRM; WHO). Shared international terms for infertility and fertility care are set out in the ICMART/WHO glossary (PMID: 28760517).

Main causes

Most cases fall into five overlapping groups: ovulation disorders, tubal factor, uterine or cervical factors, endometriosis, and age-related decline in ovarian reserve.

Ovulation disorders

Common patterns include PMOS (polyendocrine metabolic ovarian syndrome, formerly PCOS), hypothalamic suppression (stress, underweight, extreme exercise), thyroid or prolactin disorders, and premature ovarian insufficiency (POI). Many anovulatory patterns respond first to ovulation induction — for example letrozole, clomiphene, or gonadotrophins — before IVF enters the conversation (PMID: 37580314; ASRM 2026).

POI is a different diagnosis: it occurs before age 40, with cycle disturbance plus laboratory confirmation. Intermittent ovarian activity can still occur, and natural conception remains possible, but no intervention has been reliably shown to increase ovarian activity (ASRM 2025 POI guideline).

Tubal factor

Blocked or damaged tubes can stop egg pickup, fertilisation, or embryo transport. Pelvic infection, prior surgery, and endometriosis are frequent backgrounds. This is where IVF often earns its place: it bypasses the tube when repair is unlikely to help (PMID: 33642065). A communicating hydrosalpinx left untreated before IVF can still blunt results: ASRM notes that implantation and live-birth rates may be roughly halved in that setting (PMID: 33642065).

Uterine and cervical factors

Cavity-distorting fibroids, polyps, intrauterine adhesions, and congenital anomalies can hinder implantation or raise miscarriage risk. Some clinically relevant cavity findings may be better corrected before an embryo transfer.

Cervical problems — such as stenosis or mucus disorders — relate mainly to sperm passage and need a different assessment. They are not the same as implantation problems inside the uterus. ASRM notes that mucus disorders are rarely the sole or main cause of infertility (ASRM 2026 committee opinion).

Endometriosis

Endometriosis can distort pelvic anatomy, sustain inflammation, and in some cases affect egg or implantation biology. Surgery, IVF, or a sequenced plan combining the two may all be reasonable — the choice depends on stage, symptoms, age, and prior attempts.

Age and ovarian reserve

Female age is the single strongest predictor of how likely conception is (ASRM 2026 committee opinion). Egg number falls with age, while anti-Müllerian hormone (AMH) and antral follicle count estimate ovarian reserve rather than egg quality. Egg competence also declines with age, so chromosomally abnormal embryos become more common. IVF can improve cycle efficiency. It does not rewind ovarian ageing.

How evaluation usually works

A standard workup builds from history and cycle pattern, then adds targeted tests: early-cycle hormones, pelvic ultrasound, ovarian reserve markers, tubal assessment (hysterosalpingography, HSG, or an equivalent), and cavity review when needed. When a partner provides sperm, semen analysis starts in parallel.

TestWhat it clarifiesTypical timing
History and cycle reviewOvulation pattern, risk factors, prior surgeryFirst visit
Semen analysis (when a partner provides sperm)Count, motility, morphology, other male factorsIn parallel with the female workup
Basal FSH and estradiol (E2)Ovarian reserve contextCycle days 2–4
AMH and antral follicle countOvarian reserve and expected response to stimulationAMH on any cycle day; AFC on ultrasound
TSH; prolactin when clinically indicatedEndocrine contextBased on symptoms and history
Pelvic ultrasoundAnatomy, cysts, lining, antral folliclesOften early follicular phase
Tubal test (HSG, contrast ultrasound or HyCoSy, or selected laparoscopy)Patency and cavity outlineAfter menses, before ovulation
Cavity assessment (saline scan, hysteroscopy)Polyps, adhesions, distorting fibroidsWhen clinically indicated or before IVF
LaparoscopyEndometriosis, adhesions, subtle pelvic or tubal diseaseNot routine screening for every patient

Timing is not one-size-fits-all: AMH can be measured at any point in the cycle, while prolactin is generally reserved for specific clinical indications (ASRM 2026).

Laparoscopy is reserved for strong suspicion of endometriosis, dense adhesions, or a surgical question that imaging cannot settle (ASRM 2026; PMID: 32603474).

When IVF becomes a fit

IVF is usually discussed when both tubes are badly damaged, simpler care has failed, reserve is declining and time is short, a significant male factor needs intracytoplasmic sperm injection (ICSI), or natural conception is otherwise unlikely.

Common transition points include:

  1. Severe bilateral tubal disease or large communicating hydrosalpinx.
  2. Several failed ovulation-induction or intrauterine insemination (IUI) cycles.
  3. Low reserve where waiting itself is the risk.
  4. Moderate-to-severe male factor needing ICSI.
  5. Advanced endometriosis after simpler options have been exhausted.
  6. Unexplained infertility after a complete workup, usually after a few well-planned stimulated IUI cycles; IVF is considered earlier from about age 38.
  7. Situations where preimplantation genetic testing is clinically indicated.

IVF adds control over fertilisation timing, embryo selection, and transfer timing. Results still hinge on age, embryo quality, the uterine environment, and the underlying diagnosis.

Practical notes for international patients

Basic evaluation can often be completed in one or two visits, but the calendar depends on which tests are needed and where you are in the cycle. An antagonist IVF cycle typically needs about 10–14 days of ovarian stimulation on site; the actual stay varies with response and the transfer plan. A frozen transfer can be a shorter return trip later.

Bring prior hormone results, ultrasounds, HSG films, operative notes, and any genetic reports. Incomplete records can delay planning and may mean some tests need repeating.

Dr. Aksoy’s Approach

Dr. Senai Aksoy: Three decision points come up constantly in this workup — pure anovulatory PMOS, “possible hydrosalpinx” on a paper report, and the unexplained label.

When anovulation is the only barrier. If the tubes are open, semen is normal, and the main problem is that eggs are not being released, the first job is controlled ovulation — not IVF. Letrozole is usually first line. When ovulation is documented and timed intercourse is possible, I do not add IUI automatically in the first cycle just because the diagnosis is PMOS; with normal sperm the incremental gain from IUI can be limited.

Under 35, three to six ovulatory letrozole cycles are often reasonable, with a full re-check after three if there is no pregnancy. Between 35 and 37 I usually reassess after about three well-run cycles. From 38 onward — especially with long infertility or falling reserve — IVF enters the conversation earlier, but age 38 alone does not send every untreated patient straight to IVF.

AMH is not an IVF indication by itself: it mainly predicts egg yield in stimulation. In PMOS it is often high, and high does not mean high egg quality. What pushes me toward earlier IVF is the combination of age ≥38, age-discordant low AMH and AFC, long infertility, enough failed ovulatory cycles, an added male or tubal factor, or a wish for more than one child with little calendar left.

The 2023 international PCOS guideline likewise keeps letrozole first line in anovulatory PMOS without other infertility factors, and places IVF after first- and second-line ovulation treatment has failed (PMID: 37580314).

When the HSG only says “possible hydrosalpinx.” A written phrase is not an operation order. Before irreversible salpingectomy or proximal occlusion I want confirmation that a communicating hydrosalpinx is real — recurrent ultrasound fluid, a dilated distal tube on HSG that fills from the cavity, fluid reappearing in the endometrium, or laparoscopy. Unilateral disease is not automatically safe: fluid can still reach the cavity and blunt IVF.

If I only have a report without films, if spasm or pooling could explain the image, if ultrasound is clean and the HSG is borderline, or if “blocked tube” was written without describing a true hydrosalpinx, I verify first. For international patients the sequence is: DICOM or full HSG series, not the text alone; prior ultrasound and infection history; expert TVUS in Istanbul; repeat HSG or HyCoSy if doubt remains; operate only after confirmation.

When surgery is needed and anatomy allows, I prefer salpingectomy; when the tube is densely stuck to the ovary or low reserve makes ovarian blood supply a concern, proximal occlusion can be the ovary-sparing choice. The aim is not “remove a tube at all costs” — it is to stop hydrosalpinx fluid reaching the cavity while protecting the ovary. WHO guidance for confirmed hydrosalpinx before IVF likewise supports salpingectomy or tubal occlusion, with method choice guided by adhesions and surgical feasibility (WHO 2025 infertility guideline).

When the label is “unexplained.” I first check that ovulation, reserve, cavity, at least one open tube, and adequate semen assessment were truly completed. Unexplained means today’s standard tests have not shown a cause — not that nothing is wrong. Under 35 with short duration and good reserve, a brief expectant window can be reasonable; when treating, I usually try three to four cycles of oral stimulation with IUI, then move to IVF rather than stacking many gonadotrophin–IUI cycles (PMID: 32106976).

Between 35 and 37 I rarely extend beyond two to three well-planned IUI cycles. From 38, especially with long infertility or falling reserve, early IVF is often the more rational use of calendar time.

The two misconceptions I hear most: “all tests normal, so our chance must be normal,” and “unexplained means we need a long list of advanced immune or implantation tests.” Standard tests do not fully measure egg quality, tubal pickup, gamete interaction, or embryo chromosomes — but missing a label also does not obligate every experimental panel. Sometimes the better step is the age-appropriate treatment rung, not another test.

Closing line I use: “Simpler treatments are valuable when they are used in the right patient for the right duration. Sending a young woman with pure anovulation to early IVF is as wrong as leaving a woman over 38 — or with falling reserve — in months of low-probability cycles.”

Questions worth asking before deciding

Use these as a neutral checklist with your clinician — not as a sales script.

Related reading in English:

Frequently Asked Questions for Dr. Aksoy

Does female infertility always mean IVF is needed?

No. Not every woman with an infertility diagnosis needs IVF. First we need to understand why pregnancy has not happened.

In a young woman with an ovulation problem, regulating ovulation alone can be enough. In some couples IUI is enough; in others a natural pregnancy still occurs without treatment.

IVF becomes more appropriate when both tubes are closed, there is a severe male factor, or the woman is older and time is limited. My approach is not to offer every patient the most advanced treatment, but to weigh the chance of pregnancy with the least intervention in a reasonable time — and to avoid unnecessary delay, cost, and procedures.

When do you move from IUI or ovulation induction to IVF?

The two factors that matter most to me are the woman’s age and the realistic chance of pregnancy with simpler care.

In a young patient with an ovulation disorder — especially PMOS — I prefer to restore ovulation first with a medicine such as letrozole. If pregnancy does not follow after several well-monitored ovulation-induction cycles, I reassess other infertility factors.

In unexplained infertility, especially under 35, three to four cycles of ovarian stimulation with IUI are often reasonable; if those fail, moving to IVF usually makes more sense. Between 35 and 37 I set the waiting window more carefully. From 38 onward I bring IVF into the discussion earlier for most patients.

If both tubes are closed, or sperm values are clearly inadequate for IUI, I do not spend time on unnecessary IUI attempts. There is no rule that every couple must complete three IUIs; what matters is whether the next attempt still offers a meaningful chance of pregnancy.

Does a low AMH mean I need IVF right away?

No. A low AMH alone does not mean IVF is needed immediately. I see patients worry about this more than they need to.

AMH mainly tells us about ovarian reserve — and, in IVF, helps us estimate how many eggs we may obtain. It does not, on its own, reliably show egg quality or the chance of conceiving without treatment.

A 29-year-old with low AMH who ovulates regularly, has open tubes, and a partner with normal semen may still conceive spontaneously. At 40, the same AMH reading makes time much more important, because age is one of the main factors shaping egg quality.

I do not decide on IVF from the AMH result alone. I weigh age, the antral follicle count on ultrasound, how long the couple has been trying, and other infertility factors together. We do not ignore a low AMH — but one laboratory number does not send a patient straight to IVF.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.

Before getting in touch

Please note that certain services, such as sperm donation, egg donation, surrogacy and gender selection (without medical necessity), are not permitted under Turkish law.

We would like to inform you that our clinic strictly adheres to these regulations and does not offer any of these services.

Continue